Clinical trial
HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing…
NCT00349349 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00349349 |
|---|---|
| Title | HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab |
| Official title | A Single-arm, International, Multi-center Trial of HuMax-CD20, a Fully Human Monoclonal Anti-CD20 Antibody, in Patients With B-cell Chronic Lymphocytic Leukemia Who Have Failed Fludarabine and Alemtuzumab |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukaemia, Lymphocytic, Chronic |
| Intervention type | Drug |
| Interventions | ofatumumab |
| Enrollment | 223 |
| Start date | Jun 1, 2006 |
| Primary completion | May 1, 2008 |
| Completion | Jun 1, 2012 |
| First posted | Jul 7, 2006 |
| Last update posted | Jun 4, 2014 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: